Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Institut Pasteur currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 4 distinct examiners, which means that each pending matter is being handled by a different individual. This level of examiner diversity suggests that the prosecution of the portfolio is decentralized, requiring separate strategies for each application.
The workload is further distributed across 4 distinct art units, indicating that the institute's research covers several different technical niches within the biotechnology sector. LALONDE, ALEXANDRA ELIZABETH is the busiest examiner for the portfolio, currently managing 1 busiest examiner pending office action. This examiner is responsible for 1 of the 4 pending office actions currently on the docket.
For the legal team, the presence of 4 distinct examiners and 4 distinct art units necessitates a highly individualized approach to each application. There is no examiner overlap to leverage for consistency, so the 4 pending office actions must be addressed according to the specific standards of each art unit. The role of LALONDE, ALEXANDRA ELIZABETH is limited to 1 busiest examiner pending action, making her just one of four key figures in the current prosecution cycle.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LALONDE, ALEXANDRA ELIZABETH | 1 | 71.2% | +32.8% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.5% |
| DAHLE, CHUN WU | 1 | 50.2% | +51.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245987 | HIGH THROUGHPUT METHODS AND PRODUCTS FOR SARS-COV-2 SERO-NEUTRALIZATION ASSAY | KINSEY WHITE, NICOLE ERIN | 5d overdue |
| 18713519 | MEDICAL DEVICE FOR THE TARGETED APPLICATION OF A THERAPEUTIC AGENT TO THE ROUND WINDOW OF THE COCHLEA | LALONDE, ALEXANDRA ELIZABETH | — |
| 18582939 | OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS | BLUMEL, BENJAMIN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245987 | HIGH THROUGHPUT METHODS AND PRODUCTS FOR SARS-COV-2 SERO-NEUTRALIZATION ASSAY | KINSEY WHITE, NICOLE ERIN | 5d overdue |
| 18713519 | MEDICAL DEVICE FOR THE TARGETED APPLICATION OF A THERAPEUTIC AGENT TO THE ROUND WINDOW OF THE COCHLEA | LALONDE, ALEXANDRA ELIZABETH | — |
| 18582939 | OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS | BLUMEL, BENJAMIN P | — |
| 18245239 | IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS | DAHLE, CHUN WU | — |
| Art Unit | Apps |
|---|---|
| 1672 | 2 |
| 3783 | 1 |
| 1671 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18713519 | MEDICAL DEVICE FOR THE TARGETED APPLICATION OF A THERAPEUTIC AGENT TO THE ROUND WINDOW OF THE COCHLEA | LALONDE, ALEXANDRA ELIZABETH | 3783 | §102§103§112 | Non-Final OA | — | Pending | May 24, 2024 |
| 18706610 | LENTIVIRAL VECTOR FOR EXPRESSION OF HUMAN PAPILLOMAVIRUS (HPV) ANTIGENS AND ITS IMPLEMENTATION IN THE TREATMENT OF HPV INDUCED CANCERS | ALAM, DANYAL HASSAN | 1672 | §103§112DP | Non-Final OA | — | Pending | May 01, 2024 |
| 18582939 | OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS | BLUMEL, BENJAMIN P | 1671 | §102§103§112 | Non-Final OA | — | Pending | Feb 21, 2024 |
| 18245987 | HIGH THROUGHPUT METHODS AND PRODUCTS FOR SARS-COV-2 SERO-NEUTRALIZATION ASSAY | KINSEY WHITE, NICOLE ERIN | 1672 | §102§103 | Final Rejection | 5d overdue | Pending | Mar 20, 2023 |
| 18245239 | IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS | DAHLE, CHUN WU | 1641 | §103 | Non-Final OA | — | Pending | Mar 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInstitut Pasteur has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Alexandra Elizabeth Lalonde has the most, with 1 of Institut Pasteur's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
